Mark J. Ratain to Drug Industry
This is a "connection" page, showing publications Mark J. Ratain has written about Drug Industry.
Connection Strength
1.445
-
Combination therapy patents: a new front in evergreening. Nat Biotechnol. 2021 12; 39(12):1504-1510.
Score: 0.793
-
Oncology micro-cap stocks: caveat emptor! J Natl Cancer Inst. 2011 Oct 19; 103(20):1488-9.
Score: 0.391
-
Forecasting unanticipated consequences of "The Sunshine Act": mostly cloudy. J Clin Oncol. 2014 Aug 01; 32(22):2293-5.
Score: 0.118
-
Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol. 2004 Nov 15; 22(22):4442-5.
Score: 0.060
-
Inside information: Financial conflicts of interest for research subjects in early phase clinical trials. J Natl Cancer Inst. 2004 May 05; 96(9):656-61.
Score: 0.059
-
Opportunities and challenges in the development of experimental drug combinations for cancer. J Natl Cancer Inst. 2011 Aug 17; 103(16):1222-6.
Score: 0.024